SCHEMBL9911352

SCHEMBL9911352

CC(C)NCCc1cc[n+]([O-])cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 5/20 0.42
KCNH3 Q9ULD8 1/20 0.41
HTT P42858 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
LMNA P02545 4/20 0.37
ADRB2 P07550 3/20 0.37
HIF1A Q16665 3/20 0.37
SLC6A2 P23975 3/20 0.37
SLC6A4 P31645 3/20 0.37
OPRM1 P35372 3/20 0.37
OPRK1 P41145 3/20 0.37
CYP2D6 P10635 2/20 0.37
ADRB1 P08588 2/20 0.37
ADRA1A P35348 2/20 0.37
SLC6A3 Q01959 2/20 0.37
GALR3 O60755 1/20 0.37
CYP3A4 P08684 2/20 0.36
CYP2C19 P33261 1/20 0.36
ADRB3 P13945 1/20 0.36
TMEM97 Q5BJF2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9911481 0.80 SIGMAR1 (0.38) SIGMAR1SMN1; SMN2CYP3A4CYP2C19
SCHEMBL9911532 0.79 GPR84 (0.48) SIGMAR1GPR84CYP1A2
SCHEMBL13996937 0.78 L3MBTL1 (0.47) SIGMAR1HTTSMN1; SMN2LMNAADRB2
SCHEMBL12581047 0.78 TAAR1 (0.56) SIGMAR1KCNH3SMN1; SMN2LMNAHIF1A
SCHEMBL1148376 0.75 SIGMAR1 (0.68) SIGMAR1SMN1; SMN2LMNASLC6A2OPRK1
SCHEMBL23695828 0.74 SIGMAR1 (0.49) SIGMAR1HTTSMN1; SMN2LMNAADRB2
SCHEMBL7427247 0.74 CYP3A4 (0.35) KCNH3HTTSMN1; SMN2LMNACYP3A4
SCHEMBL10087662 0.74 ALDH1A1 (0.47) SIGMAR1HTTSMN1; SMN2LMNAADRB2
SCHEMBL4425592 0.72 LOXL2 (0.45) SIGMAR1KCNH3HTTSMN1; SMN2LMNA
SCHEMBL20024425 0.72 SIGMAR1 (0.53) SIGMAR1HTTSMN1; SMN2LMNAADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198458-B2 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-12 US disclosed
US-20090143370-A1 Non-nucleoside Reverse Transcriptase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-04 US disclosed
US-7517998-B2 Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus BOEHRINGER INGELHEIM INTERNATIONAL GMBH 2009-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143370-A1 Non-nucleoside Reverse Transcriptase Inhibitors RTF1, POLR1A, POLR1E SIGMAR1 303/4885KCNH3 3899/4885HTT 2993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.